Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged type 2 diabetic mice if the treatment started after stroke in a clinically relevant setting. Furthermore we characterized the Exendin-4 effects on stroke-induced neuroinflammation. Two-month-old healthy and 14-month-old type 2 diabetic/obese mice were subjected to middle cerebral artery occlusion. 5 or 50 µg/kg Exendin-4 was administered intraperitoneally at 1.5, 3 or 4.5 hours thereafter. The treatment was continued (0.2 µg/kg/day) for 1 week. The neuroprotective efficacy was assessed by stroke volume measurement and stereological counting of NeuN-positive neurons. Neuroinflammation was determined by gene expression analysis of M1/M2 microglia subtypes and pro-inflammatory cytokines. We show neuroprotective efficacy of 50 µg/kg Exendin-4 at 1.5 and 3 hours after stroke in both young healthy and aged diabetic/obese mice. The 5 µg/kg dose was neuroprotective at 1.5 hour only. Proinflammatory markers and M1 phenotype were not impacted by Exendin-4 treatment while M2 markers were significantly up regulated. Our results support the use of Exendin-4 to reduce stroke-damage in the prehospital/early hospitalization setting irrespectively of age/diabetes. The results indicate the polarization of microglia/macrophages towards the M2 reparative phenotype as a potential mechanism of neuroprotection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence, GLP-1RAs can attenuate neuroinflammation through microglial M2 polarization [76].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [76]
In the citing paper
“Moreover, in both young and aged diabetic mice subjected to MCAO, exendin-4 treatment was shown to significantly polarize microglia/macrophages towards an anti-inflammatory M2 phenotype in the injured hemisphere compared to the non-injured hemisphere [76].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“the classical proinflammatory M1 phenotype and the wound-healing reparative M2 phenotype respectively [24].”
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“In addition to direct neuroprotective effects also supported by GLP-1R expression in neurons [38], the regulation of inflammation has been suggested as one potential mechanism since Ex-4 decreases the number of microglia after stroke [16,18,19].”
InfluentialIschemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,382 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130 · cited 2×
“Similar to that shown after both spinal cord injury [40] and focal cerebral ischemia [25], we found an increased expression of both M1 and M2 markers 3 days after MCAO.”
Hu, X., Li, P., Guo, Y., Wang, H., Leak, R. K., Chen, S., Gao, Y., & Chen, J. (2012) · Stroke · doi:10.1161/strokeaha.112.659656 · Cited by 1,535 · cited 2×
“Similar to that shown after both spinal cord injury [40] and focal cerebral ischemia [25], we found an increased expression of both M1 and M2 markers 3 days after MCAO.”
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521 · cited 1×
“Inflammation is a key mediator in brain damage after stroke [20–23].”
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352 · cited 1×
“Overall, the differential stroke outcome between normal and T2D/obese mice underscores the importance to study stroke and potential therapies by using stroke models with comorbidities as recommended by the STAIR group [36].”
Gladstone, D. J., Black, S. E., & Hakim, A. M. (2002) · Stroke · doi:10.1161/01.str.0000025518.34157.51 · Cited by 635
Cited by
Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke
Xiong, X.-Y., Liu, L., & Yang, Q.-W. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.05.001 · Cited by 701
“For instance, agents or endogenous molecules such as execdin-4 (Darsalia et al., 2014), recombinant FAM19A3 (Shao et al.”
BackgroundAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“59 Darsalia, V. et al. (2012) Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats.”
BackgroundShan, Y., Tan, S., Lin, Y., Liao, S., Zhang, B., Chen, X., Wang, J., Deng, Z., Zeng, Q., Zhang, L., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1638-6 · Cited by 188
Curcumin Protects against Ischemic Stroke by Titrating Microglia/Macrophage Polarization
Liu, Z., Ran, Y., Huang, S., Wen, S., Zhang, W., Liu, X., Ji, Z., Geng, X., Ji, X., Du, H., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00233 · Cited by 184
“, 2016), and Exendin-4 (Darsalia et al., 2014) have the capacity to promote M2 polarization in microglia.”
Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?
Stuckey, S. M., Ong, L. K., Collins‐Praino, L. E., & Turner, R. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313101 · Cited by 172
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Hölscher, C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15508 · Cited by 145
“The inflammation response in the brain was reduced, too (Darsalia et al., 2014).”
BackgroundGLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 126
Lee, C., Jeon, S. J., Cho, K. S., Moon, E., Sapkota, A., Jun, H., Ryu, J. H., & Choi, J. W. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0550-2 · Cited by 136
“The dose of exendin-4 (5 μg/kg) was chosen based on a literature comparison [27, 28].”
García-Culebras, A., Durán-Laforet, V., Peña-Martínez, C., Ballesteros, I., Pradillo, J. M., Díaz-Guzmán, J., Lizasoain, I., & Moro, M. A. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18795789 · Cited by 111
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Inflammation within the neurovascular unit: Focus on microglia for stroke injury and recovery
Eldahshan, W., Fagan, S. C., & Ergul, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104349 · Cited by 104
Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103
Shpakov, A. O., Derkach, K. V., & Berstein, L. M. (2015) · Future Science OA · doi:10.4155/fso.15.23 · Cited by 100
Candeias, E., Sebastião, I., Cardoso, S., Carvalho, C., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0622-3 · Cited by 94
“[30] found that Ex-4 protected against ischemic brain damage in normal and aged obese T2D mice by modulating neuroinflammatory processes.”
BackgroundWu, H.-Y., Tang, X.-Q., Mao, X.-F., & Wang, Y.-X. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1799-17.2017 · Cited by 87
“However, a recent study reported that exenatide treatment in mice failed to inhibit the expression of proinflammatory cytokines such as TNF- , IL-6, and IL-1 in brains that were induced by ischemia and reperfusion, although it was able to reduce brain damage significantly (Darsalia et al., 2014).”
BackgroundResultInfluentialRole of microglia-neuron interactions in diabetic encephalopathy
Liu, Y., Li, M., Zhang, Z., Ye, Y., & Zhou, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.005 · Cited by 93
Bae, C., & Song, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112493 · Cited by 77
“In APP/PS1 mice (a mouse model of AD) brain, liraglutide and GLP-1 increase long-term potention (LTP) [42,58] and increase synaptic plasticity [41,55,59].”
BackgroundCooper, D. H., Ramachandra, R., Ceban, F., Di Vincenzo, J. D., Rhee, T. G., Mansur, R. B., Teopiz, K. M., Gill, H., Ho, R., Cao, B., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.041 · Cited by 79
Bułdak, Ł., Machnik, G., Bułdak, R. J., Łabuzek, K., Bołdys, A., Belowski, D., Basiak, M., & Okopień, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.008 · Cited by 84
“However it must be mentioned that exenatide was also shown rather to increase the level of markers of alternative activation than to reduce classical inflammation pathway in microglia [33].”
BackgroundGarcia-Flores, V., Romero, R., Miller, D., Xu, Y., Done, B., Veerapaneni, C., Leng, Y., Arenas-Hernandez, M., Khan, N., Panaitescu, B., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01291 · Cited by 71
“This is consistent with previous studies demonstrating that glucagonlike peptides, such as Ex4, induce an M2 macrophage polarization in vitro (115) and in vivo (116).”
ResultVergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“Moreover, in both young and aged diabetic mice subjected to MCAO, exendin-4 treatment was shown to significantly polarize microglia/macrophages towards an anti-inflammatory M2 phenotype in the injured hemisphere compared to the non-injured hemisphere [76].”
BackgroundBasalay, M. V., Davidson, S. M., & Yellon, D. M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06915-8 · Cited by 68
Shi, Y., Guo, X., Zhang, J., Zhou, H., Sun, B., & Feng, J. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.06.012 · Cited by 67
Gonçalves, A., Lin, C.-M., Muthusamy, A., Fontes-Ribeiro, C., Ambrósio, A. F., Abcouwer, S. F., Fernandes, R., & Antonetti, D. A. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-19006 · Cited by 64
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“Interestingly, the up-regulation of M2 markers demonstrates that Ex-4 promotes the polarization toward the anti-inflammatory M2 phenotype post MCAO in both aged T2DM/obese and normal mice, implying a new mechanism based on Ex-4- mediated neuroprotective efficacy (94, 135).”
BackgroundTweedie, D., Rachmany, L., Rubovitch, V., Li, Y., Holloway, H. W., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Hoffer, B. J., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.07.489 · Cited by 58
“Of the CNS pathways observed to be regulated by B-TBI, pretreatment with Ex-4 was able to reverse the B-TBI– induced changes in six of the pathways (Fig.”
BackgroundMethodInfluentialVentorp, F., Bay-Richter, C., Nagendra, A. S., Janelidze, S., Matsson, V. S., Lipton, J., Nordström, U., Westrin, Å., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-171068 · Cited by 56
“There was no effect on the levels of pro-inflammatory cytokines, although markers of wound-healing reparative microglia (M2 phenotype) were upregulated [41].”
BackgroundWu, H., Tang, X.-Q., Liu, H., Mao, X.-F., & Wang, Y. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.12.005 · Cited by 57
Ischemic stroke: From pathological mechanisms to neuroprotective strategies
Jiang, Y., Liu, Z., Liao, Y., Sun, S., Dai, Y., & Tang, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1013083 · Cited by 63
“Microglia show contradictory functions in post-stroke inflammation (19).”
BackgroundInfluentialMaskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
“One study reported a non-statistically significant reduction in pro-inflammatory markers.(25) There is also deterioration in markers of oxidative stress following AIS.”
BackgroundResultInfluentialZhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
The Implications of Microglial Regulation in Neuroplasticity-Dependent Stroke Recovery
Qiao, C., Liu, Z., & Qie, S. (2023) · Biomolecules · doi:10.3390/biom13030571 · Cited by 59
“Exendin-4, an agonist of the glucagon-like protein-1 (GLP-1) receptor, had no effect on M1 markers in microglia but increased the expression of M2 markers [245].”
BackgroundMethodIncretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T. E., Tovar-y-Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Drug repurposing for immune modulation in acute ischemic stroke
Amantea, D., & Bagetta, G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.11.006 · Cited by 50
Tsai, W.-H., Sung, F.-C., Chiu, L.-T., Shih, Y.-H., Tsai, M.-C., & Wu, S.-I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.765446 · Cited by 44
“GLP-1 has been reported to promote productions of antiinflammatory cytokines in various organs, including the adipose tissue, the pancreas, and the brain (Dobrian et al., 2011; Lee et al., 2012; Darsalia et al., 2014; Augestad et al., 2020; Reed et al., 2020).”
BackgroundDipeptidyl Peptidase‐4 Regulates Hematopoietic Stem Cell Activation in Response to Chronic Stress
Zhu, E., Hu, L., Wu, H., Piao, L., Zhao, G., Inoue, A., Kim, W., Yu, C., Xu, W., Bando, Y., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006394 · Cited by 45
“GLP-1R activation was reported to have a protective effect against brain damage in animal models.(33) Thus, in the present experiment, the GLP-1R stimulation by its agonist appears to have restored the stress-induced bone marrow HSC action via the Adrb3 signaling inactivationFigure 7.”
BackgroundDarsalia, V., Larsson, M., Nathanson, D., Klein, T., Nyström, T., & Patrone, C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.17 · Cited by 44
Self-citationHan, L., Hölscher, C., Xue, G.-F., Li, G., & Li, D. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000490 · Cited by 43
Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice
Zhang, H., Meng, J., Zhou, S., Liu, Y., Qu, D., Wang, L., Li, X., Wang, N., Luo, X., & Ma, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9854-1 · Cited by 43
Darsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
Self-citationHachuła, M., Kosowski, M., Zielańska, K., Basiak, M., & Okopień, B. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20032122 · Cited by 54
“The effect of GLP-1 analogs on the reduction of pro-inflammatory cytokines has been proven in experimental animal models [99,100].”
Lemche, E., Killick, R., Mitchell, J., Caton, P., Choudhary, P., & Howard, J. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106485 · Cited by 54
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
“Thus, GLP-1 mimetics including exendin-4 and liraglutide have neuroprotective effect on ischaemic stroke (Briyal et al., 2012; Darsalia et al., 2014; Li et al., 2009; Sato et al., 2013).”
BackgroundMi, R., Cheng, H.-F., Chen, R., Bai, B., An, L., Gao, F., & Xue, G. (2024) · Brain Circulation · doi:10.4103/bc.bc_38_24 · Cited by 39
“[42] Our study further demonstrates that following semaglutide intervention, levels of CD206 and TGF-β significantly increased at 1 day, while levels of CD68 and TNF-α markedly decreased at 1 day, 3 days, and 7 days.”
Wicha, P., Das, S., & Mahakkanukrauh, P. (2021) · Anatomy & Cell Biology · doi:10.5115/acb.20.290 · Cited by 32
“The therapeutic targets were also discussed in this present review as shown in Table 1 [46, 52, 60, 63, 64, 66-73, 76, 80, 81, 83, 88-90, 92-96].”
BackgroundLi, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
Yang, J., Yang, Y., & Chen, S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116889 · Cited by 30
Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 29
Liu, C., Sun, S., Xie, J., Li, H., Li, T., Wu, Q., Zhang, Y., Bai, X., Wang, J., Wang, X., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02811-9 · Cited by 28
“1 3 has been reported that EX-4 could exert anti-inflammatory and protective effects on the BBB and neurons by reducing oxidative stress, which may contribute to the treatment of stroke [11, 12].”
BackgroundPintana, H., Lietzau, G., Augestad, I. L., Chiazza, F., Nyström, T., Patrone, C., & Darsalia, V. (2019) · Clinical Science · doi:10.1042/cs20190180 · Cited by 30
Self-citationLiao, T., Zhang, S., Yuan, X., Mo, W., Fang, W., Zhao, S., Yang, W., Liu, H., & Rong, X. (2019) · Obesity · doi:10.1002/oby.22666 · Cited by 25
“GLP-1 analogs or dipeptidyl peptidase 4 inhibitors may prevent microglial overactivation, improve microglial synaptic plasticity, and decrease microgliosis in the hypothalamus (14-16).”
BackgroundSaad, M. A., Fahmy, M. I., Al‐Shorbagy, M. Y., Assaf, N., Hegazy, A., & El-Yamany, M. F. (2019) · Inflammation · doi:10.1007/s10753-019-01154-3 · Cited by 25
“Significant neuroprotection effects gained via GLP-1 receptor activation have been shown in several animal neurodegenerative models of stroke and Alzheimer’s disease [43, 44].”
BackgroundAugestad, I. L., Dekens, D., Karampatsi, D., Elabi, O., Zabala, A., Pintana, H., Larsson, M., Nyström, T., Paul, G., Darsalia, V., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15524 · Cited by 21
Self-citationParadigm Shift to Neuroimmunomodulation for Translational Neuroprotection in Stroke
Amantea, D., Greco, R., Micieli, G., & Bagetta, G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00241 · Cited by 25
Li, C., Fan, C., Zhao, J., Di, M., Sui, C., Han, L., & Hu, L. (2020) · Inflammation · doi:10.1007/s10753-020-01278-x · Cited by 22
L-Carnitine and extendin-4 improve outcomes following moderate brain contusion injury
Chen, H., Chan, Y. L., Linnane, C., Mao, Y., Anwer, A. G., Sapkota, A., Annissa, T. F., Herok, G. H., Vissel, B., Oliver, B. G. G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29430-6 · Cited by 24
Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Zhou, K. Q., Dhillon, S. K., Bennet, L., Gunn, A. J., & Davidson, J. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710191 · Cited by 20
““M2” markers CD206 but not Arg-1 and YM1/2 after transient MCAO in adult mice [78].”
BackgroundPerego, C., Fumagalli, S., Miteva, K., Kallikourdis, M., & Simoni, M. G. D. (2019) · Stroke · doi:10.1161/strokeaha.119.025196 · Cited by 18
Spezani, R., & Mandarim‐de‐Lacerda, C. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70400 · Cited by 25
“74 127 This polarization is at least partly mediated via cAMP/PKA signalling, a canonical downstream pathway of GLP-1R activation that has been implicated in suppressing NF-κ B activity and dampening pro-inflammatory transcriptional programs.”
Williams, D. M., Atkinson, M., & Evans, M. (2023) · Stroke · doi:10.1161/strokeaha.122.042109 · Cited by 18
Jensen, M. N., Israelsen, I. M. E., Wardman, J. H., Jensen, D. B., Andersen, D. B., Toft‐Bertelsen, T. L., Rath, M. F., Holst, J. J., ROSENKILDE, M. M., & MacAulay, N. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00652-x · Cited by 18
Protective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R
Zhang, H., Liu, Y., Cheng, L., Ma, X., & Luo, X. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.008 · Cited by 16
Bell, D. S. H., & Gonçalves, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108199 · Cited by 14
Microgliosis: a double‐edged sword in the control of food intake
Salvi, J., Andreoletti, P., Audinat, É., Balland, É., Fradj, S. B., Cherkaoui‐Malki, M., Heurtaux, T., Liénard, F., Nédélec, E., Rovère, C., et al. (2022) · FEBS Journal · doi:10.1111/febs.16583 · Cited by 18
“In addition, a treatment with exendin-4 given after an experimental stroke is neuroprotective in normal and aged T2D/ obese mice, by promoting the expression of anti-inflammatory markers by microglia (Arg1, CD206, Ym1/2) [87].”
BackgroundMichaelsen, M. K., Drasbek, K. R., Valentin, J. B., Svart, M. V., Larsen, J. B., Kruuse, C. R., Simonsen, C. Z., & Blauenfeldt, R. A. (2025) · Stroke · doi:10.1161/strokeaha.125.053075 · Cited by 15
Chung, C.-H., Chung, S., Cheng, Y., Yang, C., Jiang, P., Yang, C., & Chien, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030390 · Cited by 13
RetractedWang, W., Zhan, R., Zhou, J., Wang, J., & Chen, S. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.10.006 · Cited by 11
Lu, Z., Chan, S. W., Tu, L., Ngan, M. P., & Rudd, J. A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173528 · Cited by 8
Prehospital exenatide in hyperglycemic stroke—A randomized trial
Larsson, M., Castrén, M. K., Lindström, V., von Euler, M., Patrone, C., Wahlgren, N. G., & Nathanson, D. (2019) · Acta Neurologica Scandinavica · doi:10.1111/ane.13166 · Cited by 9
Self-citationYen, F., Chiang, J., Pan, C., Lin, B. J., Wei, J. C., & Hsu, C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.012 · Cited by 9
Milonas, D., Didangelos, T., Hatzitolios, A. I., & Τζιόμαλος, Κ. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0580-z · Cited by 8
Larsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
Self-citationThe treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
Ferrari, F., Moretti, A., & Villa, R. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105018 · Cited by 6
Han, S., Yang, Y., Liu, Z., Liu, Y., Xing, B., Wang, X., Yu, J., Ping, F., Li, W., Xu, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70692 · Cited by 8
Wang, H., Ko, H., Leung, T. W. H., Huang, J., Sai, J., Liang, Y., Li, H., Zhang, J., Cao, Q., Zang, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66167-z · Cited by 7
“Direct effects include attenuation of detrimental microglia activation 8 , promotion of M2 microglia polarization 14 , reduction of neuronal apoptosis and promotion of neurogenesis 15 , whereas indirect effects include amelioration of BBB breakdown 16 , stabilization of blood glucose, modulation of…”
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
Polarizing the immune system towards neuroprotection in brain ischemia
Amantea, D. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.169633 · Cited by 4
“Up-regulation Up-regulation of M2 markers has also been shown to underlie neuroprotection by Exendin-4, a glucagon-like receptor 1 agonist clinically used against type 2 diabetes in young healthy and in aged diabetic/obese mice subjected to middle cerebral artery occlusion (Darsalia et al., 2014).”
Neuroprotection Following Stroke
Amantea, D., & Greco, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00032-3 · Cited by 3
He, T., Geng, J., & Zhang, Z. (2017) · Translational medicine research · doi:10.1007/978-981-10-5804-2_9 · Cited by 3
Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Omidi, S., Mehrpouya, M., Oladnabi, M., Azadmehr, A., Kazemi‐Lomedasht, F., & Yardehnavi, N. (2021) · Venoms and Toxins · doi:10.2174/2666121701666211124151529 · Cited by 2
A pilot of the feasibility and usefulness of an aged obese model for use in stroke research
Learoyd, A., Calmus, R., Cunningham, C. N., England, T. J., Farr, T. D., Fone, K. C. F., Kendall, D. A., O’Sullivan, S. E., & Trueman, R. C. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16592.1
Augestad, I. L., Dekens, D. W., Karampatsi, D., Elabi, O. F., Zabala, A., Pintana, H., Larsson, M., Nyström, T., Paul, G., Darsalia, V., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-210113/v1 · Cited by 1
“Furthermore, there is a vast literature indicating that GLP-1R activation can reduce acute brain damage after stroke in rodents with (40, 49) or without T2D (reviewed in (13, 50)).”
BackgroundSelf-citationPolarization of Microglia/Macrophages in Brain Ischaemia: Relevance for Stroke Therapy
Amantea, D., Greco, R., Tassorelli, C., & Bagetta, G. (2017) · Springer series in translational stroke research · doi:10.1007/978-3-319-45345-3_12
Zhang, X., Wu, D., Li, D., Liu, J., Lei, C., Li, Y., Liu, L., Huang, D., Ge, J., & Wang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-335174/v1
“However, antidiabetic drug or antidepressant administration can inhibit and promote M1 and M2 polarization, respectively (Darsalia et al., 2014; Kalkman and Feuerbach, 2016).”
BackgroundChung, C.-H., Chung, S., Cheng, Y.-H., Wang, W.-H., Jiang, P.-H., Yang, C., & Chien, C. (2021) · Research Square · doi:10.21203/rs.3.rs-929309/v1
AVC, nouveaux traitements : place des agonistes du récepteur du GLP-1
Vergès, B. L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.07.005
Single-cell RNA sequencing reveals beneficial mechanisms of Exendin-4 in autoimmune uveitis
Wu, D., Gao, Y., Wen, Y., Zhang, Y., Chen, Y., Zhu, L., Peng, X., Pan, Z., Huang, D., Qin, S., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117483
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Metadata
- Authors
- Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C.
- Affiliations
- Karolinska Institutet (SE)
- University of Gothenburg (SE)
- Södertälje Sjukhus (SE)
- Corresponding author
- Darsalia, Vladimer
- Patrone, Cesare
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-08-07
- Volume
- 9
- Issue
- 8
- Pages
- e103114
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4125154
- OpenAlex
- W2009256046
- Cited by
- 92
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 11 · 2020: 7 · 2019: 16 · 2018: 8 · 2017: 12 · 2016: 5 · 2015: 8
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Eli Lilly and Company
- Diabetes Research and Wellness Foundation
- European Foundation for the Study of Diabetes
- AFA Försäkring
- Novo Nordisk
- Vetenskapsrådet
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Svenska Läkaresällskapet
- Diabetesfonden (DIA2013-010)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- exendin-4, type 2 diabetes, ischemic stroke, neuroprotection, microglial M2 polarization, neuroinflammation, middle cerebral artery occlusion, GLP-1 receptor agonists, inflammatory cytokines, M1/M2 microglia
- MeSH terms
- Exenatide, Animals, Brain Ischemia, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Male, Mice, Inbred C57BL, Peptides, Phenotype, Time Factors, Venoms, Biomarkers, Microglia, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Stroke, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.